Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
    • Contact Us
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
Home > Publications > Meeting Minutes > Pharmacovigilance RAE Committee > Minutes of 4th Meeting of the Pharmacovigilance Risk Assessment Expert Committee (PRAEC) held on Feburary 26, 2024

Minutes of 4th Meeting of the Pharmacovigilance Risk Assessment Expert Committee (PRAEC) held on Feburary 26, 2024

Asad Ullah Pharmacovigilance RAE Committee March 27, 2024March 27, 2024

The 4th meeting of the Pharmacovigilance Risk Assessment Expert Committee (PRAEC) was held in the Committee Room of the Drug Regulatory Authority of Pakistan (DRAP) on the 26th February, 2024. The minutes of the meeting are attached hereunder:-

Minutes of of 4th meeting of PRAEC 11_3_2024 Pages 27_48Download

Share this:

  • Twitter
  • Facebook
  • ← Rapid Alert: Drug Product; Falsified Risek 40mg Injection identified in the Market
  • Combating Substandard and Falsified Products : Public Alert Reporting →
  • Guidelines
    • Pharmaceuticals
    • Biologicals
    • Medical Devices
    • Alternative Medicines & Health Products
    • Pharmacy Services
    • Pharmacovigilance
    • Quality Assurance
  • Newsletters
  • Regulatory Procedures
  • Regulatory Fees
  • Application Forms
  • Public Consultations
    • Open Consultations
    • Closed Consultations
    • How to Submit Comments
  • Minutes of the Meetings
    • Registration Board
    • Central Licensing Board
    • Medical Devices Board
    • Enlistment Evaluation Committee
    • Clinical Studies Committee
    • Pharmacovigilance RAE Committee

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:00AM to 04:00PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem